- Home
- DGICA vs AURA Comparison
DGICA vs AURA Comparison
Compare DGICA & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGICA | AURA |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.2M | 631.6M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DGICA | AURA |
|---|---|---|
| Price | $18.49 | $6.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $21.00 | $16.60 |
| AVG Volume (30 Days) | 93.8K | ★ 865.6K |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $978,014,322.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.11 | $4.73 |
| 52 Week High | $21.06 | $9.54 |
Technical Indicators
Market Signals| Indicator | DGICA | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 45.51 |
| Support Level | $18.42 | $6.03 |
| Resistance Level | $19.54 | $7.83 |
| Average True Range (ATR) | 0.37 | 0.27 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 72.69 | 45.21 |
Price Performance
Historical ComparisonAbout DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.